New hope for Crohn's patients: drug may stop disease return after surgery
NCT ID NCT07528040
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the drug guselkumab can stop Crohn's disease from coming back after bowel surgery. About 88 adults with moderate to severe Crohn's who have had surgery will receive guselkumab and be monitored for up to 48 weeks. The main goal is to see if the disease stays away inside the bowel at 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai 10th People's Hospital, Tongji University School of Medicine
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can upadacitinib sustain remission in Crohn's disease?
- Ultrasound may help surgeons remove the right amount of bowel in Crohn's disease
- Can a special diet calm Crohn's Flare-Ups?
- Ear zap for IBD? tiny study tests nerve stimulation for gut relief
- Tiny plastics in our food may fuel Crohn's inflammation, scientists investigate
- AI could spot hidden bowel disease years earlier, new study hopes